Reaction: Sacituzumab govitecan to 1 product
- Reaction
- Reaction type
- cleavage
- Direction
- Major circulating metabolite?
- Yes
- Spontaneous?
- No
- Activity
- active
- References
- Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998 Feb 15;101(4):847-54. doi: 10.1172/JCI915. [Article]
- Sahota S, Vahdat LT: Sacituzumab govitecan: an antibody-drug conjugate. Expert Opin Biol Ther. 2017 Aug;17(8):1027-1031. doi: 10.1080/14712598.2017.1331214. Epub 2017 May 22. [Article]
- FDA Approved Drug Products: Trodelvy (sacituzumab govitecan-hziy) injection [Link]
- Comments
- Cleavage is thought to be mediated by pH changes, such as those encountered in cell lysosomes and/or the tumour microenvironment.
- Enzymes
- Not Available